Tempest Therapeutics files Form D for $7.5M exempt warrant offering
Tempest Therapeutics, Inc. filed a Form D Notice of Exempt Offering of Securities reporting a completed $7,500,000 private placement of pre-funded warrants accompanied by Series C and Series D Common Stock Purchase Warrants, with a combined exercise price of $0.804. The offering was sold to 1 investor under Rule 506(b), with first sale on 2026-09-15 and total remaining to be sold of $0. H.C. Wainwright & Co., LLC acted as placement agent, receiving a $225,000 cash placement fee equal to 7.0% of gross proceeds pl...
Key takeaways
Offering size and status: $7,500,000 total offering with $7,500,000 sold and $0 remaining, indicating a fully placed exempt offering.
Securities issued: 3,105,591 pre-funded warrants accompanied by 3,105,591 Series C and 3,105,591 Series D Common Stock Purchase Warrants, including the underlying common stock, at a combined exercise price of $0.804.
Exemption and date of first sale: Offered under Rule 506(b) with first sale on 2026-09-15; the issuer is not a registered investment company.
Investor base: 1 investor already invested; the issuer did not check the box indicating sales to non-accredited investors.
Placement agent compensation: H.C. Wainwright & Co., LLC received a $225,000 cash placement fee (7.0% of gross proceeds), $50,000 in legal fee reimbursement, and warrants to purchase 217,391 common shares at $1.0063 per share exercisable upon stockholder approval.
Issuer characteristics: Delaware corporation in the Biotechnology industry group (Health Care); principal place of business at 2000 Sierra Point Parkway, Suite 400, Brisbane, California; signed by President and CEO Matthew Angel on 2026-10-13.
Key metrics
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow TPST in real time
Get material earnings, filing, IR, and earnings-call alerts by email.